The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147.
M. R. Mahoney
No relevant relationships to disclose
J. A. Sloan
No relevant relationships to disclose
J. M. Hubbard
No relevant relationships to disclose
H. Liu
No relevant relationships to disclose
A. F. Shields
No relevant relationships to disclose
E. Chan
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genentech; ImClone Systems; Pfizer; Sanofi
Research Funding - Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech; Idera Pharmaceuticals; ImClone Systems; Lilly; Merck; MethylGene; Pfizer
R. M. Goldberg
No relevant relationships to disclose
S. Gill
No relevant relationships to disclose
M. S. Kahlenberg
No relevant relationships to disclose
S. G. Nair
No relevant relationships to disclose
D. J. Sargent
No relevant relationships to disclose
S. R. Alberts
No relevant relationships to disclose